A new study published this week in the British Medical Journal (BMJ) has determined that people taking the diabetes medication avandia, made by GlaxoSmithKline, are at greater risk for heart failure than people taking a competing drug, Actos, by Takeda Pharmaceuticals.
READ MORE AVANDIA LEGAL NEWS
The study investigators, based at Sunnybrook Health Sciences Center in Toronto, Canada, said in their article in the BMJ "Given the accumulating evidence of harm with rosiglitazone treatment and the lack of a distinct clinical advantage for the drug over pioglitazone (Actos), it is reasonable to question whether ongoing use of rosiglitazone is justified," (as quoted by Reuters).